Overview

* Zoetis Q3 2025 revenue of $2.4 bln missed analyst expectations

* Adjusted net income for Q3 2025 grows 9% organically

* Company revises full year 2025 revenue guidance due to broader macro trends

Outlook

* Zoetis ( ZTS ) revises full-year 2025 revenue guidance to $9.400 bln - $9.475 bln

* Company narrows full-year 2025 adjusted net income growth to 5.5% - 7.0%

* Zoetis ( ZTS ) maintains adjusted diluted EPS guidance at $6.30 to $6.40

Result Drivers

* U.S. SEGMENT - Revenue decreased 2% on reported basis but increased 3% organically, driven by companion animal products and livestock portfolio growth

* INTERNATIONAL SEGMENT - Revenue increased 3% on reported basis and 6% organically, driven by parasiticides and dermatology products

* REGULATORY MILESTONES - Achieved significant product approvals and geographic expansions, enhancing growth strategy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $2.40 $2.41

Revenue bln bln (11

Analysts

)

Q3 EPS $1.63

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Zoetis Inc ( ZTS ) is $192.00, about 24.8% above its November 3 closing price of $144.35

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)